P183 Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study | Zendy

AI Assistant Blog Pricing

P183 Once-daily versus twice-daily mesalazine for active ulcerative colitis: Efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.